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Hepatitis C virus (HCV), a non-cytopathic positive-stranded RNA virus, is one of 
the most common causes of chronic liver diseases such as chronic hepatitis, liver 
cirrhosis and hepatocellular carcinoma. Upon HCV infection, the majority of pa-
tients fail to clear the virus and progress to chronic hepatitis C. Chemokines are 
small chemotactic cytokines that direct the recruitment of immune cells and coor-
dinate immune responses upon viral infection. Chemokine production during 
acute HCV infection contributes to the recruitment of immune cells with antiviral 
effector functions and subsequent viral clearance. In chronic HCV infection, how-
ever, continuous production of chemokines due to persistent viral replication 
might result in incessant recruitment of inflammatory cells to the liver, giving rise 
to persistence of chronic inflammation and liver injury. In this review, we will 
summarize the roles of chemokines in acute and chronic settings of HCV infection 
and the clinical relevance of chemokines in the treatment of hepatitis C.
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INTRODUCTION
Hepatitis C virus (HCV) is a non-cytopathic positive-stranded RNA virus in the Fla-
viviridae family. It infects at least 170 million people worldwide and is a major cause 
of chronic liver disease.1-3 Upon HCV infection, 54 to 86% of patients progress to 
chronic hepatitis, and 20% of chronically infected patients develop long-term com-
plications such as liver cirrhosis and hepatocellular carcinoma.4,5 On the other hand, 
14 to 46% of HCV-infected patients undergo spontaneous viral clearance.4
The mechanisms leading to spontaneous viral clearance are not completely un-
derstood, while data support the role of T cell-mediated cellular immune responses 
as required for resolution of acute hepatitis C. Viral clearance after acute HCV in-
fection is associated with the presence of robust, broad and persistent CD4+ and 
CD8+ T cell responses against HCV, whereas progression to chronic hepatitis C is 
associated with weak and narrow T cell responses to the virus.6-9 Given the essen-
tial role of effective cellular immune responses in the control of HCV, a better un-
derstanding of the factors that coordinate cellular immune responses could reveal 
novel therapeutic and preventive strategies.Wonseok Kang and Eui-Cheol Shin
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in the pathogenesis of HCV infection, as reflected in their 
elevated levels in the peripheral blood and the liver. During 
HCV infection, T helper 1 (Th1) inflammatory CD4+ T cells 
and CD8+ T cells predominate in the liver, and liver-infiltrat-
ing T cells express Th1-associated chemokine receptors such 
as CXCR3 and CCR5.15-21 In addition to recruiting subsets of 
lymphocytes, there is evidence for compartmentalization of 
the recruited lymphocytes within the liver as well. For ex-
ample, CCR5 seems to recruit lymphocytes to portal tracts, 
and CXCR3 appears to be essential for the recruitment of 
lymphocytes into the parenchyma.22-25 Hence, Th1-associat-
ed chemokines might be of particular importance in the im-
munopathogenesis of acute and chronic HCV infection.
CXCR3 is a receptor for CXCL9 (monokine induced by 
interferon-γ, MIG), CXCL10 (interferon-γ-inducible pro-
tein-10, IP-10) and CXCL11 (interferon-inducible T-cell α 
chemoattractant, I-TAC) (Fig. 1A), and is known to be ex-
pressed in Th1 CD4+ T cells and CD8+ T cells, especially in 
effector and effector memory subsets. CCR5 is a receptor 
for CCL3 (macrophage inflammatory protein-1α, MIP-1α), 
CCL4 (macrophage inflammatory protein-1β, MIP-1β) and 
CCL5 (regulated on activation normal T cell expressed and 
secreted, RANTES) though CCL3 and CCL5 bind to other 
receptors redundantly (Fig. 1B). CCR5 is also expressed in 
effector and effector memory subsets of Th1 CD4+ T cells 
and CD8+ T cells.
Chemokines are small (8-12 kDa) chemotactic cytokines 
that direct the recruitment of immune cells to a specific site.   
Chemokines induce cell migration and activation by bind-
ing to specific G-protein coupled receptors containing sev-
en transmembrane domains that are selectively expressed 
on different target cells, thereby orchestrating immune re-
sponses during acute and chronic inflammation.10,11 In addi-
tion to their essential roles in immune responses, chemo-
kines also have diverse functions in angiogenesis, wound 
healing, hematopoiesis, lymphoid organ development, and 
regulation of embryonic development.11 Thus far, 50 differ-
ent chemokines have been identified, and are subdivided 
into four families according to the number of amino acids 
between the N-terminal cysteine residues: the CC, the 
CXC, the CX3C, and the XC families. The chemokine re-
ceptors are also subdivided accordingly into four families: 
CCR, CXCR, CX3CR, and XCR.10-12 
In order to clear viral infection, virus-specific T cells must 
traffic to the virus-infected tissues to recognize virus-infect-
ed cells and to exert effector functions. The migration of 
lymphocytes from blood into the peripheral inflammatory 
tissues is a complex multistep process involving adhesion, 
rolling, triggering, and transendothelial migration (diapede-
sis). Chemokines and their receptors are the key players in 
this whole process.13,14
Chemokines have been shown to play an important role 
Fig. 1. Schematic overview of Th1-associated chemokines and their receptors. Representative Th1-associated chemokine receptors are CXCR3 and CCR5. 
(A) CXCR3 is a receptor for CXCL9, CXCL10 and CXCL11, and is known to be expressed in Th1 CD4
+ T cells and CD8
+ T cells, especially in effector and effec-
tor memory subsets. (B) CCR5 is a receptor for CCL3, CCL4 and CCL5, though CCL3 and CCL5 bind to other receptors redundantly. CCR5 is also expressed in 
effector and effector memory subsets of Th1 CD4
+ T cells and CD8
+ T cells. MIG, monokine induced by interferon-γ; IP-10, interferon-γ-inducible protein-10; 
I-TAC, interferon-inducible T-cell α chemoattractant; MIP-1α, macrophage inflammatory protein-1α; MIP-1β, macrophage inflammatory protein-1β; RANTES, 
regulated on activation normal T cell expressed and secreted; Th1, T helper 1.
CXCL9 (MIG) CCL3 (MIP-1α) CXCL10 (IP-10) CCL4 (MIP-1β) CXCL11 (I-TAC) CCL5 (RANTES)
CXCR3 CCR1 CCR5 CCR3
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study of chimpanzees rechallenged with different genotypes 
of HCV after spontaneous clearance of initial HCV infection, 
intrahepatic mRNA levels of CXCL9 and CXCL10 were 
shown to be significantly elevated.28 Early elevation of in-
trahepatic mRNA levels and plasma levels of CXCL10, 
CXCL11, CCL4, and CCL5 were also reported in a recent 
study of chimpanzees with acute HCV infection.27 This in-
crease began and was maintained 2-8 weeks after HCV in-
fection, earlier than liver infiltration of T cells and serum 
ALT elevation. In addition to CXCR3- and CCR5-associat-
ed chemokines, CXCL8 (IL-8) expression is also known to 
be induced by in vitro HCV infection.36
In a recent study of IDUs with acute HCV infection, 
plasma levels of CXCL9, CXCL10, and CXCL11 were el-
evated, whereas CCL3 and CCL4 levels did not change 
significantly during acute HCV infection.30 A comparison 
of self-limited and chronically evolved subjects did not 
show any difference in the onset and the kinetics of early 
chemokine production,30,33 suggesting that chemokine pro-
duction most likely does not predict the outcome of acute 
HCV infection.
Despite its actions in antiviral immune responses, che-
mokine production may be impeded by HCV per se. For 
instance, HCV E2 protein attenuates the secretion of CCL3 
and CCL4,37 and HCV NS3/4A protein complex downreg-
ulates the production of CXCL10, CCL5, and CXCL8.38
To summarize, during the acute phase of HCV infection, 
Th1-associated chemokines are produced and HCV-specif-
ic T cells are recruited to the liver for viral clearance. Al-
though chemokine production does not seem to predict the 
outcome of acute HCV infection, evasion mechanisms uti-
lized by HCV interfere with the production of chemokines.
CHEMOKINES IN CHRONIC HCV 
INFECTION
 
Chronic hepatitis C is defined as infection with HCV per-
sisting for more than 6 months, and is characterized by in-
filtration of inflammatory cells.18
Although chemokine production during acute HCV in-
fection may contribute to the recruitment of antiviral T cells 
and to the subsequent viral elimination, chronic HCV infec-
tion is a completely different story. Chemokines have an es-
sential role in the development of inflammation in chronic 
HCV infection as reflected in their elevated levels in the pe-
ripheral blood and the liver.15-21 Constantly increased pro-
Given the importance of Th1 CD4+ T cells and CD8+ T 
cells in HCV infection, we will focus mainly on Th1-asso-
ciated chemokines in acute and chronic settings of HCV in-
fection, and the clinical relevance of chemokines in treating 
hepatitis C.
CHEMOKINES IN ACUTE HCV 
INFECTION
 
Acute hepatitis C is defined as the first 6 months after infec-
tion with HCV. However, symptomatic acute hepatitis C 
occurs in only about 15% of patients, and anti-HCV anti-
body is not detected at the onset of symptoms in about a 
third of infected patients.26 Accordingly, relatively a little 
information is available on the role of chemokines in acute 
HCV infection, and much of our understanding of the regu-
lation of chemokines in acute HCV infection comes from 
studies in HCV-infected chimpanzee models,27-29 or in the 
setting of seroconversion in high-risk individuals such as 
injection drug users (IDUs).30
In the early phase of HCV infection, pattern recognition 
receptors trigger production of type I interferon (IFN) in re-
sponse to HCV RNA,24,27,31-34 which is followed by produc-
tion of Th1-associated chemokines two to eight weeks after 
HCV infection.27,33 It is anticipated that this early produc-
tion of chemokines immediately induces liver infiltration of 
HCV-specific CD8+ T cells that target and lyse the virus-in-
fected hepatocytes and cause liver injury. In fact, however, 
liver infiltration of T cells and liver injury are not observed 
before 8-12 weeks after HCV infection, when chemokines 
are already being produced. A recent study showed that the 
delayed recruitment of CD8+ T cells is due to late priming 
of HCV-specific CD8+ T cells at 8-12 weeks, not to im-
paired production of chemokines. Fig. 2A illustrates the 
production of CXCR3- and CCR5-associated chemokines, 
the recruitment of CXCR3+/CCR5+ HCV-specific T cells, 
and their contribution to viral clearance and liver injury.
Several studies have assessed the dynamic changes in the 
expression of chemokines throughout the course of acute 
HCV infection in humans and chimpanzees.27-30,33,35 The 
chimpanzee studies report increased expression of CXCR3- 
and CCR5-associated chemokines in the liver and the plas-
ma.27-29 In a study of naïve chimpanzees following HCV in-
fection, intrahepatic mRNA levels of CCL3 were upregulated 
in the animals that spontaneously eradicated the virus com-
pared to those that developed chronic infection.29 In another Wonseok Kang and Eui-Cheol Shin
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antiviral functions. During the chronic phase, on the contrary, 
CXCL10 and CCL5 recruit inflammatory cells to the sites of 
viral persistence, leading to myelin destruction.
Along with CXCR3- and CCR5-associated chemokines, 
several other chemokines also have been correlated with he-
patic inflammation in chronic HCV infection. CXCL16 ex-
pression is increased in the liver, and its receptor, CXCR6, is 
expressed on a large fraction of activated liver-infiltrating in-
flammatory cells such as CD4+ T cells, CD8+ T cells, NK 
cells, and NKT cells.15 CXCL12, a CXCR4-associated che-
mokine, is also elevated in the liver and the peripheral 
blood.48 CXCL12 is produced by the LSECs and the biliary 
epithelial cells of the inflamed liver, and its expression was 
correlated with disease severity and fibrosis in chronic HCV 
infection.48 Notably, CCL21, a ligand of CCR7, is upregu-
lated in the HCV-infected liver,49 suggesting its involvement 
in the organization of inflammatory lymphoid follicles in the 
liver that are frequently observed in chronic hepatitis C.
To summarize, Th1-associated chemokines might be re-
quired for mounting effective antiviral immune responses in 
acute HCV infection. During chronic HCV infection, how-
ever, Th1-associated chemokines might contribute to the re-
cruitment of inflammatory cells, which are not necessarily 
virus-specific, to the liver. The recruited inflammatory cells 
cause chronic liver injury rather than viral clearance. Hence, 
the involvement of chemokines needs to be considered dif-
ferently during the acute and chronic stages of HCV infec-
tion (Fig. 2).
CLINICAL IMPLICATIONS OF 
CHEMOKINES IN HCV INFECTION
 
Several polymorphisms in chemokine and chemokine re-
ceptor genes have been associated with different outcomes 
of HCV infection. CCR5Δ32, a polymorphism defined by 
homozygosity for a 32-bp deletion in the CCR5 gene, has 
shown conflicting associations for control of HCV. Histori-
cally, CCR5 was found to be an essential co-receptor of HIV 
binding, and thus individuals homozygous for CCR5Δ32 
were protected from HIV infection. Even though CCR5 is 
not a co-receptor of HCV, CCR5 polymorphism was re-
garded as a predictor for the outcome of HCV infection and 
the course of HCV-related liver disease. A study by Woitas, 
et al.50 found an increased prevalence of chronic HCV in-
fection among patients with CCR5Δ32 polymorphism 
compared with healthy controls. By contrast, Mangia, et al.51 
duction of chemokines caused by persistent HCV RNA 
replication results in continuous recruitment of inflammato-
ry cells, both virus-specific and non-specific, to the liver 
and subsequent chronic liver injury without clearing the vi-
rus (Fig. 2B). Many of the liver-infiltrating HCV-specific T 
cells isolated from chronic HCV patients have been shown 
to be functionally exhausted, yet they may play a part in the 
persistence of chronic inflammation that leads to continu-
ous liver injury and long-term complications.
Several chemokines have been correlated with hepatic 
inflammation in chronic HCV infection. Among the CXC 
chemokines, CXCL10 expression is increased in the liver 
and the peripheral blood.19,24,39-43 Intrahepatic mRNA levels 
of CXCL10 were correlated with lobular inflammation,24,44 
and plasma levels of CXCL10 were correlated with necro-
inflammation.42,43 It is produced by hepatocytes and liver si-
nusoidal endothelial cells (LSECs).19,41 CXCL9 is also in-
creased in the liver and the peripheral blood.19,39,40,45 It is 
produced by LSECs and its levels are correlated with the 
grade of inflammation.19,39,40,45 CXCL11 is produced mainly 
by hepatocytes.32 Intrahepatic mRNA levels of CXCL11 
are significantly increased, and they were correlated with 
both portal and lobular inflammation.32 
Among the CC chemokines, CCR5-associated chemo-
kines are strongly expressed on portal endothelium. CCL5, 
produced by hepatocytes, LSECs and biliary epithelial cells, 
is increased in the liver and was correlated with the grade 
of inflammation.45,46 CCL3 and CCL4 are also increased in 
the liver and the peripheral blood, and are produced by he-
patocytes, LSECs and biliary epithelial cells.24,39 As a result, 
CXCR3+/CCR5+ T cells, including non-specific cells, are 
recruited to the hepatic lobule and portal tracts, where they 
exert effector functions such as cytotoxicity and cytokine/
chemokine production and induce chronic liver injury.
This phenomenon, by which chemokine production during 
the acute and chronic infection has different consequences, 
has been studied in other small animal models such as mu-
rine infection of the central nervous system (CNS) with 
mouse hepatitis virus (MHV).47 In this model, intracerebral 
MHV infection causes acute encephalomyelitis characterized 
by robust cell-mediated immune responses in which both T 
cells and macrophages infiltrate the CNS and exert antiviral 
functions, followed by a chronic demyelinating disease char-
acterized by continuous recruitment of leukocytes and their 
accumulation within the CNS. Chemokines play diverse 
roles in this process. During the acute phase, CXCL10 and 
CXCL9 recruit effector T cells to the CNS, bringing about Chemokines in HCV Infection
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Fig. 2. Roles of chemokines in acute and chronic HCV infection. (A) During acute HCV infection, CXCR3- and CCR5-associated chemokines are produced at 
2-8 weeks after HCV infection. The released chemokines contribute to viral clearance by recruiting effector Th1 CD4
+ and CD8
+ T cells. (B) In the majority of 
cases, however, viral clearance fails to accomplish, and HCV replication persists within the liver. The constant increase in the production of chemokines 
due to persistent HCV RNA replication results in continuous recruitment of inflammatory cells, both virus-specific and non-specific, to the liver and subse-
quent chronic liver injury without clearing the virus. HCV, hepatitis C virus.
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(CXCR3- and CCR5-associated chemokines)
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SUMMARY
Chemokines are important in lymphocyte recruitment to 
the liver in HCV infection. They play an essential part in or-
chestrating the antiviral immune responses during acute 
HCV infection. CXCR3-associated chemokines (such as 
CXCL9, CXCL10, and CXCL11) and CCR5-associated 
chemokines (such as CCL3, CCL4, and CCL5) seem to be 
required for effective antiviral T cell responses during the 
acute phase of HCV infection. In chronic HCV infection, on 
the contrary, HCV replicates persistently within the hepato-
cytes, thus sustaining chemokine production. As a result, 
continuous recruitment of inflammatory cells to the liver is 
provoked, and liver injury continues without viral clearance. 
Many of the liver-infiltrating HCV-specific lymphocytes 
isolated from chronic HCV patients have been shown to be 
functionally exhausted, yet they may contribute to the per-
sistence of chronic inflammation and liver injury.
In addition to their roles in liver inflammation, chemo-
kines may also be used as biomarkers of antiviral treatment 
outcomes of hepatitis C. An antagonist form of CXCL10 
was recently identified as a negative predictive marker to 
the current standard antiviral treatment. Other chemokines 
have also been suggested as candidates for biomarkers of 
treatment outcomes. CCL11 and CCL4 were suggested as 
positive predictive markers, while CXCL8 was suggested 
as a negative predictive marker. 
Several polymorphisms in chemokine and chemokine re-
ceptor genes have been associated with different outcomes 
of HCV infections. CCR5Δ32 has shown conflicting associ-
ations with the outcomes of HCV infection, whereas poly-
morphisms within chemokines such as CCL3, CCL5, and 
CCL2 were not associated with chronic HCV infection. 
Meanwhile, a polymorphism of CXCL11, defined by a 5-bp 
deletion in CXCL11 promoter, was associated with chronic 
HCV infection.
Thus, further studies of chemokines in HCV infection 
would contribute not only to understanding of immuno-
pathogenesis of hepatitis C but also to the development of 
novel therapeutics and predictive markers.
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